Drug safety is, of course, a prime focus of anyone in the pharmaceutical and biotech industries. The goal of any drug R&D project is to bring to market a safe and efficacious drug – oh yes, and ideally, create the latest blockbuster!

For monitoring drug safety, there are many tools and solutions. We were pleased to see the inclusion of Linguamatics I2E, in a recent paper from the FDA on the “Use of data mining at the Food and Drug Administration” (Duggirala et al, 2016, J Am Med Inform Assoc).

This FDA review covers a very broad range of text and data mining approaches, across both FDA databases (e.g. MAUDE, VAERS) and external data such as Medline, clinical study data, and social media.

Specifically, the FDA describe the use of I2E “to study clinical safety based on chemical structure information contained in medical literature. Linguamatics I2E enables custom searches using natural language processing to interpret unstructured text. The ability to predict the clinical safety of a drug based on chemical structures is becoming increasingly important, especially when adequate safety data are absent or equivocal.”


This Saturday, July 9, 2016, NLP-based text mining pioneers Linguamatics celebrate 15 years as the text analytics leader in the life science and healthcare markets.

Here are 15 things you may not know about Linguamatics:


Linguamatics recognized as Market Leader by analysts

(Cambridge, UK and Boston, USA – July 07, 2016)  Text analytics provider Linguamatics is pleased to announce that it has been recognized by Frost & Sullivan with a 2016 Market Leadership Award. The award is the result of extensive research conducted by market analysis experts Frost & Sullivan on the “NLP (Natural Language Processing)-Based Text Mining for Life Sciences” industry.

This new research highlights Linguamatics’ leading position in the market:

“Linguamatics has achieved a leadership position in the NLP for text mining and analytics market…with few participants operating in this technology and domain that have as many use cases as Linguamatics.” Sangeetha Prabakaran, Research Manager, Transformational Health at Frost & Sullivan

Read the full report

In the pharmaceutical sector, Linguamatics customers use text mining to gain business insights across drug discovery and development, including gene-disease mapping and target identification, clinical trial optimizations, and competitive intelligence. As the report points out, the number of potential use cases is expanding considerably:


Our established large annual conferences, such as the annual Text Mining Summit (U.S.) and Spring Text Mining Conference (Europe), are the Linguamatics annual showpiece events, but attendees also find our smaller, local events very appealing, as they offer a different, but highly valuable, experience.  These seminars, for both existing and future clients, provide a variety of presentations, end user case studies and plenty of opportunities to network and collaborate with other organizations and NLP experts.


Linguamatics recognized in inaugural KLAS report NLP 2016

(Cambridge, UK and Boston, USA – June 20, 2016)  Linguamatics is pleased to be recognized in the first report on Natural Language Processing (NLP) by highly-respected, independent healthcare IT analysts KLAS.  The report, titled “Natural Language Processing – Glimpses into the future of unstructured data mining”, will be required reading for many healthcare professionals and serves as further evidence of the growing importance of NLP within the healthcare sector.

Linguamatics are highlighted as having KLAS-validated live use in the Research and Population Health category for at-risk patients and risk adjustment, in the Coding and Documentation category for patient summary and reconciliation, and validated sales consideration in the Research Cohort ID/Clinical Trials use case.

Relevant quotes concerning Linguamatics in the KLAS report include: